| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.08 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.08 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.092 | 0.09 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.051 | 0.09 |